Setup

Turtle Beach (TBCH, ≈$200M cap, gaming peripherals) filed an 8-K on April 21, 2026 announcing two new independent directors pursuant to a March 9, 2026 Cooperation Agreement with The Donerail Group. Item 5.02 filings are usually governance housekeeping. This one has buried signal. Donerail is run by William Wyatt (ex-Starboard Event Driven head), who two months ago submitted a $1.1B unsolicited LBO bid for MarineMax (HZO) at the same 4% stake level he holds in TBCH today.

What the filing says

Two appointees, neither generic:

Lee Haspel — founding Partner at Blue Torch Capital. The conflict disclosure states TBCH is "currently exploring potential financing options with Blue Torch" — the same private credit lender whose term loan TBCH paid off eight months ago when it refinanced to Bank of America.

Daniela Kelley — ex-UiPath Global Head of SOX Compliance, ex-PwC Banking & Capital Markets director. Becomes Audit Committee Chair after the 2026 Annual Meeting. TBCH has an active ITGC material weakness as of December 31, 2025 — second consecutive year with material weaknesses.

Adjacent filings stack the picture. On December 29, 2025, BofA amended the credit agreement to exclude $10M of buybacks from the FCCR covenant calculation for trailing-twelve-month periods ending March 31 and June 30, 2026 — covenant relief six months into a new facility. FY2025 buybacks: $19M at $14.09/sh average. Stock closed April 21 at $11.58, 18% below that cost. $58M of authorization remains.

What the market thinks

Five sell-side analysts cover. Forward P/E 7.82x. FY2026 guidance $335-355M revenue, $44-48M Adjusted EBITDA. Options: put/call 0.01, ATM IV at 105th percentile, max pain $10.

Takeout math on FY26 EBITDA midpoint ($46M, ≈17.3M shares, $68M net debt): PE sponsor zone 6.5-7.5x = $13-16/sh; strategic 7.5-9x = $16-20. Midpoint $15.50. Muddle price (5.5-6x, no catalyst) ≈ $10.

Implied P(takeout) = ($11.58 − $10) / ($15.50 − $10) = 28.7%

Options corroborate: call skew and 105th-percentile IV are pricing a binary upside at roughly this magnitude.

Our estimate: 35%. Edge at $11.58 ≈ 6 points. Inside the probability error bars themselves. At a $10 entry, edge expands to ≈35 points.

Why the gap exists

The Blue Torch re-engagement appears only in a conflict-of-interest paragraph for Haspel — not the press release. The cross-ticker mirror (MarineMax bid, February 2026) is two months old and hasn't been synthesized into TBCH coverage. The convergence needs six facts across four filings: 2021 dormant Donerail acquisition proposal, 2022 settlement, June 2025 poison pill, August 2025 $10M Donerail block at $14.41, December 2025 FCCR amendment, April 2026 lender-on-board. No single filing tells the story.

Risks (ranked)

1. Narrative, not transaction. No strategic review announcement. The 2021 Donerail proposal went dormant for four years — pattern can fade again.
2. Entry at RSI 83. Historical base rate of small-caps at RSI >80 retracing ≥10% within 60d: 55-65%.
3. ITGC material weakness. Auditor signed off with no misstatements, but buyer diligence will flag it.
4. Blue Torch direction ambiguous. Committed financing = confirmation; revolver supplement = neutral; equity-linked with warrants = dilutive and caps tail.
5. Operating deterioration. Revenue -14.2% FY25. Adjusted EBITDA -29% YoY, partly masked by a $9.4M one-time insurance recovery.

Catalysts

• Early May 2026: Q1 earnings. Strategic review language, buyback pace, Donerail 13D activity.
• May 16, 2026: Options expiration. Max pain $10 — mechanical gravity.
• June 30, 2026: BofA FCCR covenant relief window for Q2 trailing-twelve-month expires.
• Q2-Q3 2026: 2026 Annual Meeting. Kelley Audit Chair effective post-meeting.
• August-September 2026: Most likely Blue Torch financing announcement window.
• April 30, 2027: Strategic transaction prediction deadline (35% P).

What would change our mind

Upgrade: 13D amendment with Donerail stake above 5%; 8-K Item 1.01 naming Blue Torch with "committed financing" language; 8-K formally announcing strategic review; second activist files 13D.

Kill: Donerail 13D amendment reducing stake; CEO employment contract extension with boilerplate CIC; ATM filing or equity-linked rescue; ITGC weakness escalates to financial restatement.

Bottom line: Thesis is real. Entry at $11.58 is not. Market-implied P already captures most of the signal. The PnL lives in pullback-entry at $10-10.50, where edge expands from 6 to 35 points.

Evidence